Indoco Remedies

Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations

Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets

Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg

Indoco Remedies shares drop 6% after US FDA issues Form 483 For Hyderabad CRO unit

Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore

Indoco Remedies shares plunge over 7% as Goa facility receives USFDA warning letter

Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK

Indoco Remedies partners with Clarity Pharma to strengthen UK presence

The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.

Indoco Remedies shares down nearly 2% after USFDA classifies Goa facility as ‘Official Action Indicated’

Indoco Remedies stock in focus following USFDA issues OAI classification

Indoco Remedies shares surge 3% after company gets USFDA approval for Generic Cetirizine Hydrochloride tablets

Indoco Remedies secures USFDA approval for Generic Cetirizine Hydrochloride tablets

Indoco Remedies reach record high of Rs 530 in intra-day trade

Indoco Remedies shares witnessed a record high of a whopping Rs 529.70 after they added 20 per cent on the BSE in the intra-day trade on Thursday.

Indoco Remedies gets USFDA approval for schizophrenia, bipolar disorder drug

The United States Food and Drug Administration, USFDA on Thursday gave approval to the drug firm Indoco Remedies.